Abstract: This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
Type:
Grant
Filed:
October 13, 2022
Date of Patent:
August 6, 2024
Assignees:
California Institute of Technology, The Rockefeller University
Inventors:
Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
Abstract: The disclosure is directed to a histidine-mutated anti-HIV antibody having one or more mutations at the residue Y53a, D58, K96, D97, N98, or T100a in the heavy chain of ibalizumab, and at the residue S26, L30, L33, Q89, Y92, S93 or Y94 in the light chain of ibalizumab. In addition, the disclosure also is directed to two histidine mutated variants with two mutations, one with mutations at the residues Y53a and Y94, and the other with mutations at the residues D58 and L30 in the heavy and light chains of ibalizumab, respectively.
Abstract: A volumetric imaging system implements obtaining raw image data of a sample volume of a sample material, the raw image data comprising light field data of the sample volume acquired using a microlens array disposed in front of a camera; and analyzing the raw image data using an image analysis pipeline configured to localize the objects of interest in the raw image data to obtain classified image data in which the objects of interest have been identified, the image analysis pipeline being configured to process the raw image data to improve signal extraction at depth in the scattering material to maximize localization accuracy.
Abstract: A multi-photon imaging system includes a laser module having a first channel for outputting a two-photon excitation laser pulse and a second channel for outputting a three-photon excitation laser pulse. The system further includes a first optical path for guiding the two-photon laser pulse from the first channel of the laser module and a second optical path for guiding the three-photon laser pulse from the second channel of the laser module. A microscope is also provided for simultaneously receiving the two-photon laser pulse from the first optical path and the three-photon laser pulse from the second optical path, and simultaneously, or with well controllable delays, delivering the two-photon laser pulse and the three-photon pulse to a target volume. The system further includes a photodetector configured to collect photons generated within the target volume in response to simultaneous excitation of the target volume by both the two-photon laser pulse and the three-photon laser pulse.
Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection against SARS-CoV-2 infections.
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Abstract: This disclosure provides novel broadly neutralizing anti-tick-borne encephalitis virus (TBEV) antibodies. The disclosed anti-TBEV antibodies represent a novel therapeutic strategy for preventing or treating diseases or infections caused by various tick-borne flaviviruses, including TBEV.
Abstract: The present description relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. Aureus and VISA.
Type:
Grant
Filed:
May 24, 2021
Date of Patent:
November 28, 2023
Assignee:
The Rockefeller University
Inventors:
Vincent A Fischetti, Anu Daniel, Chad Euler
Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
Type:
Application
Filed:
February 22, 2023
Publication date:
November 16, 2023
Applicants:
The Rockefeller University, California Institute of Technology
Inventors:
Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
Abstract: A multi-photon imaging system includes a laser module having a first channel for outputting a two-photon excitation laser pulse and a second channel for outputting a three-photon excitation laser pulse. The system further includes a first optical path for guiding the two-photon laser pulse from the first channel of the laser module and a second optical path for guiding the three-photon laser pulse from the second channel of the laser module. A microscope is also provided for simultaneously receiving the two-photon laser pulse from the first optical path and the three-photon laser pulse from the second optical path, and simultaneously, or with well controllable delays, delivering the two-photon laser pulse and the three-photon pulse to a target volume. The system further includes a photodetector configured to collect photons generated within the target volume in response to simultaneous excitation of the target volume by both the two-photon laser pulse and the three-photon laser pulse.
Abstract: The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXR? agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.
Abstract: Single-domain antibodies that bind the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) spike protein are disclosed. The single-domain antibodies include binding domains that bind epitopes of the Spike ectodomain inside and outside the receptor binding domain. The single-domain antibodies can be used for multiple purposes including in the research, diagnosis, and prophylactic or therapeutic treatment of COVID-19.
Type:
Application
Filed:
August 20, 2021
Publication date:
October 19, 2023
Applicants:
The Rockefeller University, Seattle Children's Hospital d/b/a Seattle Children's Research Institute, New York University
Inventors:
Brian T. Chait, Michael P. Rout, John Aitchison, Fred David Mast, Jean Paul Olivier, David Fenyo
Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
Type:
Application
Filed:
April 7, 2023
Publication date:
September 7, 2023
Applicants:
The Rockefeller University, California Institute of Technology
Inventors:
Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
Abstract: Compositions and methods disclosed concern an isogenic population of in vitro human embryonic stem cells comprising a disease form of the Huntingtin gene (HTT) at the endogenous HTT gene locus in the genome of the cell; wherein the disease form of the HTT gene comprises a polyQ repeat of at least 40 glutamines at the N-terminus of the Huntingtin protein (HTT). The cell lines of the disclosure comprise genetically-defined alterations made in the endogenous HTT gene that recapitulate Huntington's Disease in humans. Furthermore, the cell lines have isogenic controls that share a similar genetic background. Differentiating cell lines committed to a neuronal fate and fully differentiated cell lines are also provided and they also display phenotypic abnormalities associated with the length of the polyQ repeat of the HTT gene. These cell lines are used as screening tools in drug discovery and development to identify substances that fully or partially revert these phenotype abnormalities.
Type:
Grant
Filed:
February 24, 2017
Date of Patent:
June 13, 2023
Assignee:
The Rockefeller University
Inventors:
Ali Brivanlou, Albert Ruzo, Alessia Deglincerti, Tomomi Haremaki, Fred Etoc
Abstract: An optical system for the detection of skin disease, such as melanoma, acquires images of a lesion on a subject's skin at different wavelengths and utilizes a sweeping arm rotating about the lesion in a clock-like sweep to produce diagnostically relevant metrics and classifiers from the image data so as to enhance detection of the skin disease.